Camrelizumab in different PD-L1 expression cohorts of pre-treated advanced or metastatic non-small cell lung cancer: a phase II study.

Jin-Ji YangCheng HuangYun FanHongming PanJifeng FengLiyan JiangXing-Ya LiXiao-Qing LiuJian-Ping XiongYan-Qiu ZhaoYing ChengRui MaJie WangYina WangYan-Hui LiuDong-Mei LinTao WangWei ShiJianjun ZouYi-Long Wu

Published in: Cancer immunology, immunotherapy : CII (2021)

Camrelizumab showed improved efficacy compared with historical data of the second-line chemotherapy in pre-treated advanced/metastatic NSCLC. Patients with positive PD-L1 expression derived greater benefit from camrelizumab. Camrelizumab has a manageable safety profile.

Keyphrases

phase ii study
small cell lung cancer
locally advanced
squamous cell carcinoma
open label
electronic health record
big data
advanced non small cell lung cancer
newly diagnosed
radiation therapy
placebo controlled